Results and Publications

Since its inception in 2008, the CFR has made remarkable progress. We have advanced our research priorities, generated significant core research reagents and established a highly productive working infrastructure. CFR investigators have leveraged their results into federally financed research grants, thus increasing the resources supporting frontotemporal dementia research. Maximizing both private and public support of frontotemporal dementia research is a central goal of the CFR and The Bluefield Project.

To date, publications whose work was supported by CFR funding include:


  • Seeley, W. W. Mapping Neurodegenerative Disease Onset and Progression. Cold Spring Harb Perspect Biol. (2017).

  • Holler, C. J. et al. Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by GRN Mutations. eNeuro (2017).

  • She, A. et al. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia. Cell Chem Biol 24, 892–906.e5 (2017).

  • van de Sluis, B. et al. News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1. Curr Opin Lipidol 28, 241–247 (2017)

  • Meeter, L. H. et al. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 13, 406–419 (2017).

  • Zhou, X. et al. Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nat Commun 8, 15277 (2017).

  • Cheng, C. et al. Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. Curr Protoc Hum Genet 92, 21.8.1–21.8.21 (2017).

  • Arrant, A. E. et al. Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia. Brain (2017).

  • Ward, M. E. et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Trans Med (2017).

  • Krabbe, G. et al. Microglial NFκB-TNFα hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. PNAS 114, 5029–5034 (2017).

  • Wasser, C. R. & Herz, J. Reelin: Neurodevelopmental Architect and Homeostatic Regulator of Excitatory Synapses. JBC 292, 1330–1338 (2017).

  • Kao, A. W. et al. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 31, 1245 (2017).

  • Mason, A. R. et al. The Receptor-Interacting Serine/Threonine Protein Kinase 1 (Ripk1) Regulates Progranulin Levels. JBC (2017).

  • Spinelli, E. G. et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. (2017).

  • Amick, J. & Ferguson, S. M. C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. Traffic (2017). 


  • Miller, Z. A. et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture. Neurol Neuroimmunol Neuroinflamm 3, e301 (2016).

  • Amick, J., et al. C9orf72 binds SMCR8, localizes to lysosomes and regulates mTORC1 signaling. Mol. Biol. Cell (2016).

  • Nicholson, A. M. & Rademakers, R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol 1–13 (2016).

  • Ranasinghe, K. G. et al. Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurol (2016).

  • Santos-Santos, M. et al. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurol. 73:733-742 (2016).

  • Nicholson, A. M. et al. Prosaposin is a regulator of progranulin levels and oligomerization. Nat Commun. 7, 11992 (2016).

  • Arrant, A. et al. Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test. Genes Brain Behav (2016).
  • Lui, H et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell 165, 921–935 (2016).
  • Tsai, R. M. & Boxer, A. L. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. (2016).
  • Wasser, C. R. & Herz, J. Splicing therapeutics for Alzheimer's disease. EMBO Mol Med 8, 308–310 (2016).
  • Pottier, C et al. Genetics of FTLD: Overview and what else we can expect from genetic studies. J Neurochem (2016)
  • Almeida, S. et al. Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. Neurobiol Aging (2016).


  • Minami, S. S. et al. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists. Biochemical Pharmacology (2015).
  • Lee, S. & Huang, E. J. Modeling ALS and FTD with iPSC-derived neurons. Brain Research (2015)
  • Arrant, A. E. et al. Effects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient Mice. eNeuro 2, (2015).
  • Kao, P. F. et al. Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP. Ann Neurol. (2015).
  • Ossenkoppele, R. et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain awv191 (2015).
  • Gowrishankar, S. et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. PNAS (2015).
  • Salazar, D. A. et al. The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels. J. Neurosci 35, 9315–9328 (2015).
  • Ferguson, S. M. Beyond indigestion: emerging roles for lysosome-based signaling in human disease. Current Opinion in Cell Biology 35, 59–68 (2015).
  • Villeneuve, S. et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138, 2020–2033 (2015).
  • Cho, S.-H. et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J. Neurosci 35, 807–818 (2015).


  • Minami, S. S. et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med (2014).
  • Sephton, C. F. et al. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proceedings of the National Academy of Sciences 111, E4769–78 (2014).
  • Lee, S. E. et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain awu248 (2014).
  • Warmus, B. A. et al. Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. J Neurosci 34, 16482–16495 (2014).
  • van Blitterswijk, M. et al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegeneration 9, 38 (2014).
  • Ward, M. E. et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. Journal of Experimental Medicine 177, 311 (2014)
  • Ferrari, R. et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13, 686–699 (2014).
  • Nicholson, A. M. et al. Progranulin protein levels are differently regulated in plasma and CSF. Neurology (2014)
  • van Blitterswijk et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 


  • Scherling et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. (2013) pp.
  • Lee et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Human Molecular Genetics (2013) pp.
  • Perry and Miller. Frontotemporal dementia. Semin Neurol (2013) vol. 33 (4) pp. 336-41
  • Ravenscroft et al. Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiol Aging (2013) vol. 34 (9) pp. 2235.e11-3
  • van Blitterswijk et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) vol. 81 (15) pp. 1332-41
  • Judy et al. A shift to organismal stress resistance in programmed cell death mutants. PLoS Genet (2013) vol. 9 (9) pp. e1003714
  • Nguyen et al. Progranulin: at the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab (2013)
  • Almeida et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol (2013)
  • Nicholson et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem (2013)
  • Chen et al. Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and Is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells. J Neurosci (2013) vol. 33 (21) pp. 9202-9213
  • Miller et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatr (2013)
  • Filiano et al. Dissociation of Frontotemporal Dementia-Related Deficits and Neuroinflammation in Progranulin Haploinsufficient Mice. J Neurosci  vol. 33 (12) pp. 5352-536 (2013)
  • Nguyen et al. Secreted progranulin is a homodimer and is not a component of high-density lipoproteins (HDL). J Biol Chem (2013)
  • Halabi et al. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer disease and associated disorders vol. 27 (1) pp. 74-83 (2013)


  • Blitterswijk et al. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Current Opinion in Neurology. vol. 25 (6) pp. 689-700 (2012)
  • Henry et al. Neuropsychological, behavioral, and anatomical evolution in right temporal variant frontotemporal dementia: A longitudinal and post-mortem single case analysis. Neurocase (2012)
  • Rutherford et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology vol. 79 (7) pp. 717-8 (2012)
  • Roberson, E. Mouse models of frontotemporal dementia. Ann Neurol. vol. 72 (6) pp. 837-49 (2012)
  • Armakola et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nature Genetics vol 44(12):1302-9 (2012)
  • Almeida et al. Induced Pluripotent Stem Cell Models of Progranulin-Deficient Frontotemporal Dementia Uncover Specific Reversible Neuronal Defects. Cell Rep vol 2(4):789-98 (2012)
  • Martens et al. Progranulin deficiency promotes neuroinflammation and neuron loss in toxin-induced CNS injury. JCI. vol 122(11):3955-9 (2012)
  • Sephton et al. TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. J. Biol Chem vol. 393 (7) pp. 589-94 (2012)
  • Seeley et al. Frontotemporal Dementia: What Can the Behavioral Variant Teach Us about Human Brain Organization? Neuroscientist vol. 18 (4) pp. 373-85 (2012)
  • Rademakers R et al. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol vol. 8 (8) pp. 423-34 (2012)
  • Sha et al. Frontotemporal dementia due to C9ORF72 mutations: Clinical and imaging features. Neurology vol. 79 (10) pp. 1002-11 (2012)
  • Zhou et al.  Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron vol. 73 (6) pp. 1216-27 (2012)
  • Rutherford et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology vol. 79 (7) pp. 717-8 (2012)
  • Dries et al. Extracting β-amyloid from Alzheimer's disease. Proc Natl Acad Sci USA vol. 109 (9) pp. 3199-200 (2012)
  • Cenik et al. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem vol.  287 (39) pp. 32298-32306 (2012)
  • Dewey et al. TDP-43 aggregation in neurodegeneration: Are stress granules the key? Brain Res (2012).


  • Rabinovici et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011).
  • Gozal et al. Aberrant Septin 11 is Associated with Sporadic Frontotemporal Lobar Degeneration. Mol Neurodegener (2011).
  • Lee et al. Clinical characterization of bvFTD due to FUS neuropathology. Neurocase (2011).
  • Kocerha et al. Altered microRNA expressionin frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. BMC Genomics (2011).
  • Almeida et al. Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disultide isomerase family proteins. PLoS One (2011).
  • Wexler et al. Genome-wide analysis of the Wnt1 transcriptional network implicates neurodegenerative pathways. Science Signaling (2011).
  • Rosen et al. Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency. Neuron (2011).
  • Nicholson et al. Human genetics as a tool to identify progranulin regulators. J Mol Neurosci (2011).
  • Cho et al. CSCR1 modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimers disease. J Biol Chem (2011).
  • Finch et al. TMEM106B regulates progranulin leels and the penetrance of frontotemporal lobar degeneration in GRN mutation carriers. Neurology (2011).
  • Cenik et al. SAHA (Vorinostat) upregulates progranulin transcription: A rational therapeutic approach to frontotemporal dementia. JBC (2011).
  • Kao et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci USA (2011).


  • Rohrer et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology (2010).
  • Dewey et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol (2010).
  • Carrasquillo et al. Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Human Genet (2010).
  • Sephton et al. Identification of neuronal RNA targets of TDP-43-containing Ribonucleoprotein complexes. J Biol Chem (2010).

  • Chen et al. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA.  (2010). 107(26):12011-16
  • Forster et al. Emerging topics in Reelin function. European Journal of Neuroscience, (2010). Vol. 31: 1511–18.
  • Sephton et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem (2010). 285(9):6826-34. 
  • Jiao et al. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS ONE (2010). vol. 5 (5) pp. e10551.
  • Barmada et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associate with familial amyotrophic lateral sclerosis. J. Neurosci (2010). 13:639-649
  • Barmada et al. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease associated pathways. Neursci. Rev (2010). 21: 251-272


  • Daub et al. High-content screening of primary neurons: ready for prime time. Curr Opin Neurobiol (2009). 19(5):537-43.
  • Coppola et al. Gene Expression Study on Peripheral Blood Identifies Progranulin Mutations. Annals of Neurology (2008). 64(1):92-96